Biotechnology company Mucosis B.V. will present SynGEM, a needle-free vaccine that prevents respiratory syncytial virus (RSV) infections, at a vaccine conference this week,.
SynGEM's biotechnology stimulates mucosal immunities, deterring infectious diseases.
“This is an excellent opportunity to present the evidence behind the breakthroughs we are making in treating infectious diseases,” Mucosis CEO Thomas Johnston said. “Our advances in both the delivery mechanism and efficacy of RSV vaccines are setting Mucosis apart in this competitive market.”
The presentation will share details about animal study models and the development of Mucosis’ specialized formula for the F vaccine antigen.
“Our prefusion F antigen construct used in SynGEM is potentially able to generate antibodies 40-600 times more potent in virus neutralization compared to the current RSV treatment used in infants," Mucosos Chief Scientific Officer Dr. Kees Leenhouts said. "Our new data demonstrating the vaccine’s immunogenicity efficacy and safety in animal models supports the prophylactic potential of SynGEM across the various target age groups and confirms the value of the unique and stable prefusion-like F form of the antigen we have developed.”
The presentation will occur at Vaccines 2014, which will be held in London from Oct. 20-22.